Skip to main content

Table 1 Demographic, clinical, and prescription characteristics of the study population at baseline

From: An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study

Demographics N = 319
Gender, n (%) n = 319
Female 189 (59.2)
Males 130 (40.8)
Age, years n = 318
Mean (SD) 63.1 (13.4)
Median (min–max) 64.0 (28.0–92.0)
Clinical characteristics N = 319
Anticancer treatment, n (%) n = 319
Chemotherapy 111 (34.8)
Targeted therapy 106 (33.2)
Radiotherapy 30 (9.4)
Hormonotherapy 19 (6.0)
Combined therapya 53 (16.6)
Localization of xerosisb, n (%) n = 319
Lower limbs 191 (59.9)
Upper limbs 173 (54.2)
Trunk 159 (49.8)
Neckline 127 (39.8)
Hands 113 (35.4)
Face/ears 94 (29.5)
Feet 90 (28.2)
Neck 71 (22.3)
Scalp 42 (13.2)
Genitals 28 (8.8)
Xerosis severity gradec, n (%) n = 301
Grade 1 93 (30.9)
Grade 2 152 (50.5)
Grade 3 56 (18.6)
Prescriptions N = 319
Study product frequency of application, n (%) n = 317
Once daily 126 (39.8)
Twice daily 149 (47.0)
Thrice daily or more 42 (13.2)
Study product duration of prescription, days n = 313
Mean (SD) 30.2 (11.6)
Other topical or systemic treatmentsd, n (%) n = 312
Yes 77 (24.7)
No 235 (75.3)
  1. Abbreviations: N number of patients in the whole study population, n number of patients for whom data were collected, SD standard deviation. aCombined therapy comprised 31 patients with chemotherapy and targeted therapy; 7 patients with chemotherapy and radiotherapy; 5 patients with hormonotherapy and targeted therapy; 4 patients with chemotherapy and hormonotherapy; 3 patients with hormonotherapy and radiotherapy; 2 patients with chemotherapy, hormonotherapy, and radiotherapy; and 1 patient with chemotherapy, hormonotherapy, and targeted therapy. bPatients may have had xerosis on multiple parts of the body. cNational Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE, version 4.0) scale for dry skin comprising three grades: grade 1 = covering < 10% of the body surface area (BSA) and no associated erythema or pruritus; grade 2 = covering 10–30% of BSA and associated erythema or pruritus, limiting instrumental activities of daily living (ADL); grade 3 = covering > 30% BSA and associated with pruritus, limiting self-care ADL. dPatients may have had more than one concomitant treatment